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ABSTRACT NG-Test Carba 5 is a rapid in vitro multiplex immunoassay for the phe-
notypic detection and differentiation of five common carbapenemase families (KPC,
OXA-48-like, VIM, IMP, and NDM) directly from bacterial colonies. The assay is simple
to perform and has recently received U.S. Food and Drug Administration clearance.
A method comparison study was performed at geographically diverse medical cen-
ters (n  3) in the United States, where 309 Enterobacterales and Pseudomonas
aeruginosa isolates were evaluated by NG-Test Carba 5 (NG Biotech, Guipry, France),
the Xpert Carba-R assay (Cepheid, Inc., Sunnyvale, CA), the modified carbapenem in-
activation method (mCIM), the EDTA-modified carbapenem inactivation method, and
disk diffusion with carbapenems. Colonies from tryptic soy agar with 5% sheep
blood (blood agar) and MacConkey agar were tested, and the results were com-
pared to those obtained by a composite reference method. Additionally, a fourth
medical center performed a medium comparison study by evaluating the perfor-
mance characteristics of NG-Test Carba 5 from blood, MacConkey, and Mueller-Hinton
agars with 110 isolates of Enterobacterales and P. aeruginosa. These results were
compared to the expected genotypic and mCIM results. For the multicenter method
comparison study, the overall positive percent agreement (PPA) and the overall neg-
ative percent agreement (NPA) of NG-Test Carba 5 with the composite reference
method were 100% for both blood and MacConkey agars. The medium comparison
study at the fourth site showed that the PPA ranged from 98.9% to 100% and that
the NPA ranged from 95.2% to 100% for blood, MacConkey, and Mueller-Hinton
agars. NG-Test Carba 5 accurately detected and differentiated five common carbap-
enemase families from Enterobacterales and P. aeruginosa colonies on commonly
used agar media. The results of this test will support a streamlined laboratory work
flow and will expedite therapeutic and infection control decisions.
KEYWORDS Enterobacterales, NG-Test Carba 5, Pseudomonas aeruginosa, Xpert
Carba-R, carbapenemase, eCIM, mCIM
According to the Centers for Disease Control and Prevention (CDC), carbapenem-resistant Enterobacterales and carbapenem-resistant Pseudomonas aeruginosa are
considered urgent and serious threats, respectively, in the United States (1–3). Mech-
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anisms of resistance among carbapenem-resistant organisms (CRO) are broadly divided
into 2 groups: (i) carbapenemase-producing CRO (CP-CRO) and (ii) non-CP-CRO; i.e.,
CRO resistant to carbapenems due to non-carbapenemase-mediated mechanisms,
such as membrane permeability defects in combination with extended-spectrum
-lactamase (ESBL) or AmpC -lactamase production. The former are more aggressively
targeted by infection control and antimicrobial stewardship teams due to the ease of
transmission of carbapenemase genes among Gram-negative bacteria through the
horizontal transfer of plasmids, which often contain additional antimicrobial resistance
determinants that further limit treatment options (4–8). Moreover, infections caused by
CP-CRO are associated with increased mortality compared to those caused by non-CP-
CRO (5, 9–11). Thus, carbapenemase detection among CRO has become increasingly
important in recent years for patient care, public health, and infection control initia-
tives.
The detection and differentiation of carbapenemases from cultured isolates in
clinical and public health laboratories normally involve the initial detection of de-
creased susceptibility to carbapenems followed by the broad detection of carbapen-
emase production by a phenotypic method (e.g., a carbapenem hydrolysis assay, such
as CarbaNP, or the modified carbapenem inactivation method [mCIM]) and/or detec-
tion of specific carbapenemase genes by molecular-based assays (e.g., the Xpert
Carba-R assay [Cepheid, Inc., Sunnyvale, CA]) (12, 13). Although there has been signif-
icant progress over the past decade in developing phenotypic assays with improved
performance characteristics and rapid, sample-to-answer molecular approaches, there
are still limitations to these methods, such as the inability to detect all carbapenemase
variants, labor intensity, work flow, turnaround time, and cost (12, 13).
NG-Test Carba 5 (NG Biotech, Guipry, France) is an immunoassay intended to
streamline the process of carbapenemase detection and differentiation in routine
clinical laboratories. It is a rapid diagnostic test (15 min) based on the immunochro-
matographic detection of the five most common carbapenemase families (KPC, OXA-
48-like, VIM, IMP, and NDM) directly from bacterial colonies. Within the OXA-48-like
family, NG-Test Carba 5 has demonstrated inclusivity with at least 15 different con-
firmed variants, including OXA-163, OXA-181, and OXA-232 (14). The purpose of this
multicenter study was to establish the performance characteristics of the NG-Test Carba
5 test from tryptic soy agar with 5% sheep blood (blood agar) and MacConkey agar to
obtain U.S. Food and Drug Administration (FDA) clearance of NG-Test Carba 5 for in
vitro diagnostic use as well as to evaluate its performance from Mueller-Hinton agar
compared to that from blood and MacConkey agars.
MATERIALS AND METHODS
Bacterial isolates. Testing was performed at three academic medical centers in the United States,
including the Johns Hopkins University School of Medicine (site 1; Baltimore, MD), Weill Cornell Medicine
(site 2; New York, NY), and the Medical College of Wisconsin (site 3; Milwaukee, WI). Each site had to pass
a proficiency testing panel prior to initiation of the study.
Retrospective and prospective isolates were included in the study, for a total of 309 Enterobacterales
isolates (n  240) and P. aeruginosa isolates (n  69) (see Table S1 in the supplemental material). The 121
retrospective challenge isolates were distributed among the three clinical sites and consisted of refer-
ence bank isolates (American Type Culture Collection, National Collection of Type Cultures, CDC,
International Health Management Associates, JMI Laboratories, Laboratory Specialists, Inc.) and clinical
isolates from California hospitals and the University of Illinois.
Each clinical site contributed its own retrospective isolates (collected 6 months from the testing
date [n  38]) and prospective isolates (collected 6 months from the testing date [n  150]) for the
remaining 188 clinical isolates (Table S1). The inclusion criteria included any Enterobacterales or P.
aeruginosa isolate identified by standard-of-care testing and included isolates that were susceptible or
not susceptible to a carbapenem(s) or that contained a previously determined mechanism of carbap-
enem resistance. The prospective isolates were collected from various specimen types (e.g., urine, rectal
swabs/stools, blood, respiratory specimens, wounds, sterile fluids, tissues, etc.).
All isolates were subcultured twice prior to testing. Isolates recovered from frozen stocks were
streaked onto blood agar with an ertapenem disk placed (including P. aeruginosa isolates) between the
3rd and 4th quadrants and incubated at 35  2°C overnight. After overnight incubation, growth selected
from around the ertapenem disk was streaked from the first subculture to blood agar and MacConkey
agar plates with an ertapenem disk placed between the 3rd and 4th quadrants and incubated at
35  2°C for 18 to 24 h.
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NG-Test Carba 5. Blood and MacConkey agar overnight cultures were tested with NG-Test Carba 5
following the manufacturer’s instructions. Using a 1-l loop, three colonies were touched and inoculated
into a 1.5-ml microcentrifuge tube containing 5 drops of extraction buffer. After the buffer was
inoculated with colonies, the tube was vortexed for approximately 3 to 5 s. Mucoid, or so-called sticky,
colonies required a longer vortex time of approximately 10 to 15 s. Using a small transfer pipette
provided in the NG-Test Carba 5 kit, 100 l of the suspension was inoculated into the NG-Test Carba 5
sample well. After 15 min, the test was visually examined for the presence or absence of the control and
test lines. To avoid biased result interpretation, NG-Test Carba 5 results were visually examined for
isolates grown on blood and MacConkey agars by separate study team members. Quality control (QC)
was performed every day of testing and included a negative control (Klebsiella pneumoniae ATCC
BAA-1706) and one positive control for each target (KPC-producing K. pneumoniae ATCC BAA-1705,
OXA-48-producing K. pneumoniae NCTC 13442, VIM-producing K. pneumoniae NCTC 13439, IMP-
producing Escherichia coli NCTC 13476, and NDM-producing K. pneumoniae ATCC BAA-2146).
Composite reference method. The NG-Test Carba 5 assay was compared to a composite reference
method. The composite reference method included (i) phenotypic detection of carbapenemase produc-
tion by mCIM and (ii) molecular detection of carbapenemase genes by the U.S. FDA-cleared Xpert
Carba-R real-time PCR assay (1, 12, 13, 15, 17–22). Table 1 summarizes how the NG-Test Carba 5 results
were interpreted based on the results of the composite reference method prior to discrepant analysis.
The composite reference method was chosen because NG-Test Carba 5 detects the carbapenemase
enzymes themselves and the mCIM is necessary to determine the expression of the gene product
detected by Xpert Carba-R. In addition to the composite reference standard, carbapenem (ertapenem
[10 g] for Enterobacterales only, imipenem [10 g], and meropenem [10 g]) antimicrobial susceptibility
testing (AST) by disk diffusion and the EDTA-modified carbapenem inactivation method (eCIM) were
performed, and the results were interpreted according to Clinical and Laboratory Standards Institute
(CLSI) guidelines (1, 19–22). All comparator methods were performed from the blood agar plate. Positive
and negative controls for Xpert Carba-R, disk diffusion, mCIM, and eCIM were performed on each day of
testing following manufacturer or CLSI guidelines, as appropriate (1, 18–22).
Discrepant analysis. Organisms that had discrepant NG-Test Carba 5 and composite reference
method results were further analyzed by targeted PCR and sequencing by an independent reference
laboratory to confirm the presence or absence of the carbapenemase genotype and variant (Table 1).
Isolates were grown overnight at 35  2°C on blood agar, and DNA was purified using a QIAcube
instrument following the recommendation of the manufacturer (Qiagen, Gaithersburg, MD). The Entero-
bacterales isolates were screened for the presence of the carbapenemase families blaKPC, blaOXA-48, blaIMP,









No. of results by
pre-discrepant analysisaXpert Carba-R mCIMb
   True positive 169
   False positive 0
   False positive 0
   False positive 7c
   False negative 0
   True negative (lack of or
low-level expression)
1d
   True negative (other off-target
carbapenemase)
15e
   True negative 121f
aThe results on blood and MacConkey agars were the same. Results are shown by enzyme type and not by
isolate. The 172 on-target carbapenemase-producing isolates demonstrated a total of 176 positive NG-Test
Carba 5 results due to four isolates that coproduced two target carbapenemases.
bmCIM, modified carbapenem inactivation method.
cOf the 7 false-positive results, results for IMP for 6 isolates (3 Enterobacterales and 3 Pseudomonas
aeruginosa isolates) were positive by NG-Test Carba 5 and negative by Xpert Carba-R. The remaining false-
positive result was for a Klebsiella oxytoca isolate that was positive for both KPC and NDM by NG-Test Carba
5 but negative for NDM by Xpert Carba-R. PCR and bidirectional sequencing confirmed all 7 NG-Test Carba
5 results.
dOne Enterobacter cloacae prospective isolate was resistant to ertapenem (zone diameter, 18 mm) but
susceptible to imipenem and meropenem and harbored the blaKPC gene as determined by Xpert Carba-R.
The isolate was negative by both mCIM and NG-Test Carba 5, indicating a lack of or low-level expression.
eThese 15 true-negative results were found for 7 Enterobacterales isolates and 8 P. aeruginosa isolates. Of the
Enterobacterales isolates, four harbored blaSME. A carbapenemase gene was not detected in the remaining
three isolates, and these isolates likely had false-positive mCIM results due to ESBL and/or AmpC expression
combined with permeability defects. Among the P. aeruginosa isolates, one harbored the blaGES gene and
the remaining seven harbored non-carbapenemase -lactamase genes.
fOne P. aeruginosa isolate and one Klebsiella aerogenes isolate led to indeterminate mCIM results and were
negative by Xpert Carba-R and NG-Test Carba 5.
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blaVIM, blaNDM, and blaGES by multiplex PCR using published primers (23, 24). The P. aeruginosa isolates
were also screened for blaSPM and blaGIM (23, 24). -Lactamase genes were amplified and sequenced in
their entirety. The amino acid sequence was compared to the sequences available in databases
maintained by the National Center for Biotechnology Information (NCBI; www.ncbi.nlm.nih.gov) to
identify enzyme variants. Whole-genome sequencing was performed on an Illumina (Illumina, San Diego,
CA) and/or Nanopore (Oxford Nanopore Technologies, Oxford, England) sequencing platform to elabo-
rate upon any further discrepant results.
Additional medium comparison study. A secondary study (separate from the multicenter clinical
trial) was performed. A fourth site (site 4; Washington University, St. Louis, MO) evaluated the perfor-
mance of NG-Test Carba 5 from isolates grown on blood, MacConkey, and Mueller-Hinton agars and
compared the results to the expected molecular and mCIM results for 110 previously molecularly
characterized Enterobacterales isolates (n  105) and P. aeruginosa isolates (n  5). Sixty of these organ-
isms were a subset of the retrospective challenge isolates that were supplied by Hardy Diagnostics (Santa
Maria, CA) and were also evaluated by each of the three clinical trial sites (sites 1 to 3). The remaining
50 isolates were from the Washington University strain bank (Table S2). Of these, 34 originated from
Barnes-Jewish Hospital and 16 were from Pakistan (hospital environmental isolates or isolates recovered
from urine). Each isolate had a genotypic resistance mechanism previously determined using molecular
methods (targeted PCR, Xpert Carba-R, or whole-genome sequencing). Primary cultures were prepared
by streaking all isolates to blood agar with an ertapenem disk placed between the 3rd and 4th quadrants.
All isolates (including P. aeruginosa isolates) were subsequently streaked to blood and MacConkey agars
with an ertapenem disk placed between the 3rd and 4th quadrants. Disk diffusion was performed, and
the result for each organism with ertapenem on Mueller-Hinton agar was interpreted following CLSI
guidelines (19, 20). Three colonies (blood and MacConkey agars) or spots (Mueller-Hinton agar) around
the ertapenem disk were touched with a 1-l loop and inoculated into the extraction buffer before
completing the NG-Test Carba 5 procedure.
Statistical analysis. All data were entered into and analyzed in Microsoft Excel software for positive
percent agreement (PPA) and negative percent agreement (NPA). Upper- and lower-bound 95% confi-
dence intervals (CIs) were calculated and are shown in the appropriate tables (25, 26).
RESULTS
NG-Test Carba 5 versus composite reference method. The pre-discrepant analysis
NG-Test Carba 5 results versus the results of the composite reference method are
summarized in Table 1. The overall pre-discrepant analysis PPA was 100% (95%
confidence interval [CI], 97.8% to 100.0%), and the NPA was 95.1% (95% CI, 90.3% to
97.6%), regardless of medium type. Prior to discrepant analysis, there were seven
false-positive results associated with four Enterobacterales and three P. aeruginosa
isolates (Table 2). The results for the seven isolates were concordant between NG-Test
Carba 5 and mCIM but were negative by the Xpert Carba-R assay.
Among the Enterobacterales, three of the isolates (two Enterobacter cloacae isolates,
one Serratia marcescens isolate) were considered false positive for IMP by NG-Test Carba
5. Targeted PCR and bidirectional sequencing revealed that these three isolates were
confirmed to harbor the blaIMP-8 gene, in favor of the NG-Test Carba 5 result. Interest-
ingly, blaIMP-8 is predicted to be detected by Xpert Carba-R, based on in silico analysis,
but this has not been tested analytically by Cepheid (16). The fourth isolate, Klebsiella
oxytoca, was considered to have a true-positive result for KPC and a false-positive result
for NDM, based on the composite reference standard (Table 2). This isolate was later
confirmed by PCR and bidirectional sequencing to coproduce blaKPC and blaNDM-1.
Three P. aeruginosa isolates were false positive for IMP by NG-Test Carba 5 but
negative by Xpert Carba-R (Table 2). All three were positive by mCIM and confirmed to
have a blaIMP gene by PCR and sequencing (blaIMP-7, blaIMP-15, blaIMP-19). Of note,
blaIMP-7 and blaIMP-15 are not predicted to be detected by Xpert Carba-R, while blaIMP-19
is predicted to be detected based on in silico analysis but has not been tested
analytically by the manufacturer (16, 18).
Table 3 summarizes the post-discrepant analysis of NG-Test Carba 5 performance
versus the composite comparator method. The overall PPA was 100% (95% CI, 97.8% to
100%) and the overall NPA was 100% (95% CI, 97.3% to 100%), regardless of the
organism group or agar medium used.
Carbapenem susceptibility testing. Of the 240 Enterobacterales isolates that were
included in the analysis (Table 3), 196 (81.7%) were not susceptible to a carbapenem
(intermediate or resistant). Of the Enterobacterales isolates, 79.2% (190/240), 73.8%
(177/240), and 74.2% (178/240) were not susceptible to ertapenem, imipenem, and
meropenem, respectively. Among the 69 P. aeruginosa isolates, 64 (92.8%) were not
Jenkins et al. Journal of Clinical Microbiology
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susceptible to a carbapenem. Of those, 81.2% (56/69) and 92.8% (64/69) were not
susceptible to imipenem and meropenem, respectively.
mCIM and eCIM analysis. Table 4 shows the agreement of the NG-Test Carba 5
results with the mCIM and eCIM results. When the mCIM and eCIM results were
compared to the NG-Test Carba 5 results for Enterobacterales, the overall PPA was 93.6%
(95% CI, 87.3% to 96.9%) for serine -lactamase detection and 94.2% (95% CI, 84.4% to
98.0%) for metallo--lactamase (MBL) detection. The overall NPA was 100%. Seven
Enterobacterales isolates showed a positive mCIM result and a negative NG-Test Carba
5 result. Four S. marcescens isolates were positive for the carbapenemase gene blaSME.
A carbapenemase gene was not detected in the remaining three isolates, and these
likely had false-positive mCIM results due to ESBL and/or AmpC expression combined
with permeability defects. Four organisms coproduced a serine carbapenemase and
MBL (KPC plus NDM [n  1], OXA-48 plus NDM [n  2], OXA-48 plus VIM [n  1]); in
these instances, the serine -lactamase masked the presence of the MBL, resulting in a
false-negative eCIM result.
The overall PPA for NG-Test Carba 5 compared to mCIM for both Enterobacterales
and P. aeruginosa was 92% (95% CI, 87.2% to 95.1%), and the NPA was 100% (95% CI,
96.9% to 100%). Among the P. aeruginosa isolates, there were eight with mCIM-positive
results that were negative by NG-Test Carba 5. One P. aeruginosa isolate harbored the
blaGES gene. The remaining seven P. aeruginosa isolates harbored noncarbapenemase
-lactamase genes, including blaOXA-2 (n  5) and blaOXA-10 (n  1), and all of the
isolates carried the chromosomal -lactamase genes blaOXA-50 and blaPAO (n  7).
These results may explain the positive mCIM results since the original multicenter mCIM
evaluation identified a false-positive P. aeruginosa isolate that coharbored the
-lactamase genes blaOXA-2, blaOXA-50, and blaPAO (1).
Additional medium comparison study. Table 5 shows the performance results for
NG-Test Carba 5 by agar type (site 4). The PPA for Enterobacterales was 100% (95% CI,
95.7% to 100%), 100% (95% CI, 95.7% to 100%), and 98.8% (95% CI, 93.6% to 99.8%) for
blood, MacConkey, and Mueller-Hinton agars, respectively. The NPA for Enterobactera-
les was 100% (95% CI, 80.6% to 100%), 93.8% (95% CI, 71.7% to 98.9%), and 100% (95%
CI, 80.6% to 100%) for blood, MacConkey, and Mueller-Hinton agars, respectively. One
Providencia rettgeri isolate from the Washington University strain bank was false
TABLE 3 Composite reference method versus NG-Test Carba 5 results by isolate tested from blood or MacConkey agar, post-discrepant
analysisa










TP FP FN TN Low High Low High
Enterobacterales (240) KPC (n  83) 83 0 0 157 100.0 95.6 100.0 100.0 97.6 100.0
OXA-48-like (n  17) 17 0 0 223 100.0 81.6 100.0 100.0 98.3 100.0
VIM (n  10) 10 0 0 230 100.0 72.3 100.0 100.0 98.4 100.0
IMP (n  7) 7 0 0 233 100.0 64.6 100.0 100.0 98.4 100.0
NDM (n  35) 35 0 0 205 100.0 90.1 100.0 100.0 98.2 100.0
OXA-48  NDM (n  2) 2 0 0 238 100.0 34.2 100.0 100.0 98.4 100.0
OXA-48  VIM (n  1) 1 0 0 239 100.0 20.7 100.0 100.0 98.4 100.0
KPC  NDM (n  1) 1 0 0 239 100.0 20.7 100.0 100.0 98.4 100.0
Overall (n  156) 156 0 0 84 100.0 97.6 100.0 100.0 95.6 100.0
Pseudomonas aeruginosa (69) KPC (n  2) 2 0 0 67 100.0 34.2 100.0 100.0 94.6 100.0
OXA-48-like (n  0) 0 0 0 69 NA NA NA 100.0 94.7 100.0
VIM (n  9) 9 0 0 60 100.0 70.1 100.0 100.0 94.0 100.0
IMP (n  5) 5 0 0 64 100.0 56.6 100.0 100.0 94.3 100.0
NDM (n  0) 0 0 0 69 NA NA NA 100.0 94.7 100.0
Overall (n  16) 16 0 0 53 100.0 80.6 100.0 100.0 93.2 100.0
Enterobacterales P. aeruginosa (309) Overall (n  172) 172 0 0 137 100.0 97.8 100.0 100.0 97.3 100.0
aThe results on blood and MacConkey agars were the same. Testing was performed at sites 1 to 3. TP, true positive; FP, false positive; TN, true negative; FN, false
negative; NA, not applicable; 95% CI, 95% confidence interval.
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TABLE 4 NG-Test Carba 5 agreement with mCIM and eCIM by isolate from three clinical sites, pre-discrepant analysisa
Test, organism groupb
mCIM or




AgreementResult No. of isolates
mCIM
Enterobacterales Positive 163 KPC 83 PPA, 156/163  95.7%




OXA-48  VIM 1
OXA-48  NDM 2
KPC  NDM 1
Negative 7d
Negative 76 Negative 76 NPA, 76/76  100%
(95% CI, 95.2–100.0%)
P. aeruginosa Positive 24 KPC 2 PPA, 16/24  66.7%





Negative 44 Negative 44 NPA, 44/44  100%
(95% CI, 92.1–100.0%)
Enterobacterales  P. aeruginosa Positive 187 KPC 85 PPA, 172/187  92.0%




OXA-48  VIM 1
OXA-48  NDM 2
KPC  NDM 1
Negative 15d,e
Negative 120 Negative 120 NPA, 120/120  100%
(95% CI, 96.9–100.0%)
mCIM  eCIM, Enterobacterales Serine -lactamase 112 KPC 83 PPA, 102/112  93.6%




OXA-48  VIM 1
OXA-48  NDM 2
KPC  NDM 1
Negative 7d
MBL 51 KPC 0 PPA, 49/51  94.2%




OXA-48  VIM 0
OXA-48  NDM 0
KPC  NDM 0
Negative 0
Negative 76 Negative 76 NPA, 76/76  100%
(95% CI, 95.2–100.0%)
aTesting was performed at sites 1 to 3. mCIM, modified carbapenem inactivation method; eCIM, EDTA-modified carbapenem inactivation method.
bOne K. aerogenes isolate and one P. aeruginosa isolate had an indeterminate mCIM result and were NG-Test Carba 5 negative. These results are not shown here.
cThe NG-Test Carba 5 result for each isolate was the same from blood and MacConkey agars.
dFour S. marcescens isolates were positive for the carbapenemase gene blaSME. A carbapenemase gene was not detected in the remaining three isolates, and these
isolates were likely false positive due to ESBL and/or AmpC expression combined with permeability defects.
eOne P. aeruginosa isolate had a blaGES gene. Seven P. aeruginosa isolates were confirmed to harbor noncarbapenemase -lactamase genes by whole-genome
sequencing, likely indicating false-positive mCIM results.
fUpon retesting by mCIM and eCIM, a positive result for MBL was obtained for one of the two IMP isolates and the NDM isolate.
gUpon retesting by mCIM and eCIM, a positive result for serine -lactamase was obtained for one of the two OXA-48 isolates. OXA-48-producing isolates are known to
produce false-positive eCIM results.
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negative for IMP by NG-Test Carba 5 from Mueller-Hinton agar (positive mCIM result,
negative NG-Test Carba 5 result, molecularly characterized to harbor blaIMP-27). One
Proteus mirabilis isolate, also from the Washington University strain bank, was consid-
ered false positive for IMP by NG-Test Carba 5 from MacConkey agar (negative mCIM
result, positive NG-Test Carba 5 result, molecularly characterized to harbor blaIMP-27).
For P. aeruginosa, the PPA was 100% (95% CI, 51% to 100%) and the NPA was 100%
(95% CI, 56.6% to 100%) for all agar types.
DISCUSSION
CP-CROs may be harbored in the human gastrointestinal tract and can be acquired in
hospital settings or through food and travel (27, 28). While colonization may not always
escalate into infection, the importance of identifying patients colonized and/or infected
with CP-CROs has increased, since carbapenemase genes can easily spread between
Gram-negative organisms in hospitals and in the community via plasmids (27, 28). Further-
more, detection of a nonendemic or rarely encountered carbapenemase can be important
for infection control practices. On the therapeutic front, the importance of rapid carbap-
enemase differentiation immediately after carbapenem resistance detection is critical for
treatment, as many novel compounds targeted against CP-CROs have specific activity
TABLE 5 NG-Test Carba 5 medium comparison study by isolate, pre-discrepant analysisa
Plate
Organism group










TP FP FN TN Low High Low High
Blood agar Enterobacterales (101) KPC (n  26) 26 0 0 75 100.0 87.1 100.0 100.0 95.1 100.0
OXA-48-like (n  15) 15 0 0 86 100.0 79.6 100.0 100.0 95.7 100.0
VIM (n  7) 7 0 0 94 100.0 64.6 100.0 100.0 96.1 100.0
IMP (n  6) 6 0 0 95 100.0 61.0 100.0 100.0 96.1 100.0
NDM (n  27) 27 0 0 74 100.0 87.5 100.0 100.0 95.1 100.0
OXA-48  NDM (n  3) 3 0 0 98 100.0 43.9 100.0 100.0 96.2 100.0
OXA-48  VIM (n  1) 1 0 0 100 100.0 20.7 100.0 100.0 96.3 100.0
Overall (n  85) 85 0 0 16 100.0 95.7 100.0 100.0 80.6 100.0
P. aeruginosad (9) VIM (n  1) 1 0 0 8 100.0 20.7 100.0 100.0 67.6 100.0
IMP (n  3) 3 0 0 6 100.0 43.9 100.0 100.0 61.0 100.0
Overall (n  4) 4 0 0 5 100.0 51.0 100.0 100.0 56.6 100.0
Enterobacterales 
P. aeruginosa (110)
Overall (n  89) 89 0 0 21 100.0 95.9 100.0 100.0 84.5 100.0
MacConkey agar Enterobacterales (101) KPC (n  26) 26 0 0 75 100.0 87.1 100.0 100.0 95.1 100.0
OXA-48-like (n  15) 15 0 0 86 100.0 79.6 100.0 100.0 95.7 100.0
VIM (n  7) 7 0 0 94 100.0 64.6 100.0 100.0 96.1 100.0
IMP (n  6) 6 1b 0 94 100.0 61.0 100.0 98.9 94.3 99.8
NDM (n  27) 27 0 0 74 100.0 87.5 100.0 100.0 95.1 100.0
OXA-48  NDM (n  3) 3 0 0 98 100.0 43.9 100.0 100.0 96.2 100.0
OXA-48  VIM (n  1) 1 0 0 100 100.0 20.7 100.0 100.0 96.3 100.0
Overall (n  85) 85 1 0 15 100.0 95.7 100.0 93.8 71.7 98.9
Enterobacterales 
P. aeruginosa (110)
Overall (n  89) 89 1 0 20 100.0 95.9 100.0 95.2 77.3 99.2
Mueller-Hinton
agar
Enterobacterales (101) KPC (n  26) 26 0 0 75 100.0 87.1 100.0 100.0 95.1 100.0
OXA-48-like (n  15) 15 0 0 86 100.0 79.6 100.0 100.0 95.7 100.0
VIM (n  7) 7 0 0 94 100.0 64.6 100.0 100.0 96.1 100.0
IMP (n  6) 5 0 1c 95 83.3 43.7 97.0 100.0 96.1 100.0
NDM (n  27) 27 0 0 74 100.0 87.5 100.0 100.0 95.1 100.0
OXA-48  NDM (n  3) 3 0 0 98 100.0 43.9 100.0 100.0 96.2 100.0
OXA-48  VIM (n  1) 1 0 0 100 100.0 20.7 100.0 100.0 96.3 100.0
Overall (n  85) 84 0 1 16 98.8 93.6 99.8 100.0 80.6 100.0
Enterobacterales 
P. aeruginosa (110)
Overall (n  89) 88 0 1 21 98.9 93.9 99.8 100.0 84.5 100.0
aThese data are for 50 isolates from the Washington University isolate collection and 60 isolates from the challenge panel provided by Hardy Diagnostics. Testing was
performed at site 4. TP, true positive; FP, false positive; TN, true negative; FN, false negative; 95% CI, 95% confidence interval.
bOne P. mirabilis isolate was mCIM negative, IMP positive by NG-Test Carba 5, and characterized to harbor blaIMP-27 by whole-genome sequencing.
cOne P. rettgeri isolate was mCIM positive, IMP negative by NG-Test Carba 5, and characterized to harbor blaIMP-27 by whole-genome sequencing.
dThe performance with P. aeruginosa was the same for each agar type, so only data for blood agar are shown.
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depending on the carbapenemase type (e.g., novel -lactam–-lactamase inhibitor com-
binations have no activity against MBLs, and certain agents, but not all of them, have
activity against particular serine carbapenemases) (29, 30).
Overall, the multicenter clinical trial found that the PPA and the NPA for NG-Test
Carba 5 compared to the composite reference method after discrepant analysis were
100%, regardless of the medium type. In this study, carbapenemase-producing Entero-
bacterales isolates were obtained from diverse body sites and source locations. In the
future, with some enhancements, this test may be further validated to detect carbap-
enemases directly from different specimen types, hence augmenting the range of
clinical applications (31, 32). Although all P. aeruginosa isolates prospectively enrolled
at the clinical sites were negative by NG-Test Carba 5, 86.5% (32/37) of the P. aeruginosa
isolates exhibited carbapenem resistance but were mCIM negative. These isolates may
have mutations in the OprD porin combined with the hyperexpression of AmpC and/or
efflux pumps (33). In these instances, the resistance mechanism is less likely to be
plasmid mediated, but the resistance pattern remains a concern. Although carbapen-
emase production is a small contributor to carbapenem resistance among P. aeruginosa
isolates in the United States (2% of carbapenem-resistant P. aeruginosa isolates
produce carbapenemases), there have been increasing reports of VIM-producing P.
aeruginosa isolates in long-term care facilities and import to areas of nonendemicity
due to medical tourism in areas of endemicity (34–38). Thus, it is important for clinical
laboratories to have diagnostic tools available for carbapenemase detection in the
event of changing epidemiology or an outbreak in the hospital setting.
The mCIM and eCIM test procedures showed excellent diagnostic performance
characteristics, further supporting their use for broadly detecting carbapenemase
activity. In this study, the majority of organisms positive by the NG-Test Carba 5 assay
exhibited an mCIM zone diameter of 6 mm (i.e., growth of the E. coli ATCC 25922
reporter strain up to the disk), which confirmed the ease of interpretation of the mCIM
test. The major drawback of the mCIM for clinical laboratories is the requirement of an
overnight incubation step. This is a risk due to the high mortality rates associated with
these infections or the potential for transmission in the hospital setting (5, 9–11).
However, with the implementation of the NG-Test Carba 5 assay, the time to an
actionable result is reduced to 15 min for a phenotypic result for the five most
common carbapenemase families.
A similar lateral flow assay, Resist-4 O.K.N.V., developed by Coris BioConcept (Gem-
bloux, Belgium) (which detects KPC, NDM, OXA-48, and VIM enzymes), is yet to be
cleared by the U.S. FDA but has shown good performance for all carbapenemases
except NDM enzymes (39). An additional limitation of this assay is that it does not
detect IMP enzymes and requires two devices for detecting the major carbapenemase
families. Other commercially available phenotypic carbapenemase detection assays
include the Rapidec CarbaNP assay (bioMérieux, Marcy-l’Étoile, France), while commer-
cially available genotypic assays include the FilmArray blood culture identification
panel (BioFire Diagnostics, LLC, Salt Lake City, UT), the Verigene EPlex assay (Luminex
Corporation, Austin, TX), the BD Max CPO Detect assay (Becton, Dickinson and Com-
pany, Franklin Lakes, NJ), and the Xpert Carba-R assay, among others. To our knowl-
edge, NG-Test Carba 5 is the most streamlined assay among the nongenotypic methods
and offers differentiation among the major carbapenemase families. While direct-from-
specimen platforms display excellent diagnostic characteristics, they require an upfront
capital investment, which may not be possible for all laboratories. For laboratories that
lack an efficient assay for carbapenemase detection and differentiation or institutions
that look to simplify testing and reduce the use of molecular assays due to budgeting
constraints, NG-Test Carba 5 can be an effective option to streamline the work flow and
potentially reduce cost without affecting the overall quality of results.
Ultimately, these findings demonstrate the excellent performance of NG-Test Carba
5 for detecting and differentiating carbapenemase-producing Enterobacterales and P.
aeruginosa isolates. The results of other single-center evaluations of NG-Test Carba 5 in
France and the United Kingdom have been published and showed performance data
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similar to those observed in our multicenter study, the first multicenter study to be
described (40, 41). This was also the first study, to the authors’ knowledge, to thor-
oughly evaluate the performance of NG-Test Carba 5 with colonies recovered from
MacConkey agar, an important culture medium for the cultivation of Gram-negative
bacteria. Furthermore, this study implemented blinding techniques and a standardized
inoculation method with NG-Test Carba 5. These aspects of the study allowed for
unbiased interpretation of the results when examining the NG-Test Carba 5 results and
avoided extreme variations in sampling techniques across operators.
The inclusion of selective pressure on each agar medium is considered a limitation of
the study, as most labs do not routinely place antimicrobial disks. P. aeruginosa isolates are
intrinsically resistant to ertapenem; thus, no selective pressure was considered to have been
applied for this species (19).
It has been well described that carbapenemase detection and differentiation are no
longer solely for infection control or epidemiological purposes but are also of utmost
importance for successful outcomes in patient care and antimicrobial stewardship due to
the availability of novel antimicrobial agents that target specific carbapenemases (39–43).
An area of future research will focus on the performance of NG-Test Carba 5 when applied
directly to different specimen types, such as positive blood culture broths and urine. If
successful, this will widen the clinical applicability of the NG-Test Carba 5 system.
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